Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: March 26, 2019
Expires: March 25, 2020
15 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat or manage advanced or metastatic breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the mechanism of action of cyclin-dependent kinase 4/6 inhibitors, including differences among available and emerging agents
  • Compare and contrast the dosing and efficacy of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer
  • Select the appropriate cyclin-dependent kinase 4/6 inhibitor for patients according to their efficacy, safety, and patient characteristics
  • Identify common toxicities of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer, including gastrointestinal toxicity and neutropenia

Activity Description

Recently, there have been significant advances in the development of agents that target critical pathways involved in resistance to endocrine therapy in HR-positive/HER2-negative breast cancer, such as cyclin-dependent kinase (CDK) 4/6 inhibitors,  palbociclib, abemaciclib, and ribociclib.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on CDK4/6 inhibitors for the treatment of advanced HR-positive/HER2-negative breast cancer.

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the use of CDK4 and CDK6 inhibitors for the treatment of HR-positive/HER2-negative advanced or metastatic breast cancer so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices with their patients.


Adam M. Brufsky, MD, PhD, FACP
Professor of Medicine / Associate Chief, Hematology-Oncology / Associate Director, Translational Research
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Adam M. Brufsky, MD, PhD, FACP
  • Adam M. Brufsky, MD, PhD, FACP, reported a financial interest/relationship or affiliation in the form of: Received consulting fees from Lilly USA; Novartis Pharmaceuticals Corp; Pfizer, Inc; Amgen, Inc; and AstraZeneca Pharmaceuticals LP.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.